Anthem Biosciences, ₹3,395 crore IPO was fully subscribed by Day 2, with strong interest from non-institutional investors, Retail, and Qualified Institutional Buyer segments. The public issue was opened on July 14, 2025 and will remain open for bidding until July 16, 2025.
• Price Band Per Share: ₹540–₹570
• Minimum Investment Required: ₹14,040
• Lot size: 26 shares
• Maximum Lot: 13
• Bid Opening Date: July 14, 2025
• Bid Closing Date: July 16, 2025
• Allotment date: July 17, 2025
• Listing Date: July 21, 2025
Maximum Subscription Amount for the Retail Investors: ₹2,00,000
About the Company
Anthem Biosciences, founded in 2006, is a Bengaluru-based CRAMS firm serving global pharmaceutical clients with integrated drug research and manufacturing services.
Anthem Biosciences Limited operates as a Contract Research, Development & Manufacturing Organization serving pharmaceutical companies, globally. The company provides end-to-end drug development and manufacturing services to its clients.
Check here for the details
| Subscription Category Details | No. of Times |
| Retail -Individual Investor (RIIs) | 5.64 |
| Retail -Employees | 6.6 |
| Non-Institutional Investor (NII) | 42.36 |
| Qualified Institutional Buyer (QIB) | 182.65 |
| Total Subscription | 63.86 |
Check here for the details
| Subscription Category Details | No. of Times |
| Retail -Individual Investor (RIIs) | 5.61 |
| Retail -Employees | 6.56 |
| Non-Institutional Investor (NII) | 42.35 |
| Qualified Institutional Buyer (QIB) | 182.65 |
| Total Subscription | 63.85 |
Check here for the details
| Subscription Category Details | No. of Times |
| Retail -Individual Investor (RIIs) | 4.68 |
| Retail -Employees | 5.2 |
| Non-Institutional Investor (NII) | 37.31 |
| Qualified Institutional Buyer (QIB) | 73.65 |
| Total Subscription | 31.28 |
Check here for the details
| Subscription Category | No. of Times |
| Retail -Individual Investor (RIIs) | 3.86 |
| Retail -Employees | 4.55 |
| Non-Institutional Investor (NII) | 27.79 |
| Qualified Institutional Buyer (QIB) | 11.88 |
| Total Subscription | 11.25 |
Check here for the details
| Subscription Category | No. of Times |
| Retail -Individual Investor (RIIs) | 3.23 |
| Retail -Employees | 3.65 |
| Non-Institutional Investor (NII) | 21.13 |
| Qualified Institutional Buyer (QIB) | 4.59 |
| Total Subscription | 7.44 |
STRENGTH: The company has reported a consistent increase in revenue form operations. It increased from Rs.1056.92 crore in FY23 to Rs.1,419.37 crore in FY24 to Rs.1,844.55 crore in FY25.
WEAKNESS: The company has an outstanding financial indebtedness amounting to Rs.1,08.95 crore. Any failure to repay loans can harm the operations and financials.
Ajay Bhardwaj: 42%
Ishaan Bhardwaj: 10.16%
Ganesh Sambasivam: 9.23%
Check here for the details
| Total Issue Size | 4,40,70,682 |
| Total Bids Received | 14,50,57,068 |
| Total Bids Received at Cut-off price | 3,88,71,300 |
| No. of times issue is subscribed | 3.29 |
Subscription Details:
Retail -Individual Investor (RIIs): 2.07x | Retail -Employees: 2.57x | Non-Institutional Investor (NII): 9.72x | Qualified Institutional Buyer (QIB): 0.59x | Total Subscription: 3.28x
